EUCTR2007-006645-41-NL进行中（未招募）不适用
The (cost)effectiveness of paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients. - CEPS
Sint Lucas Andreas Hospital0 个研究点开始时间: 2008年5月29日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Hemodialysis patients of 18 years and older.
- •- Secondary hyperparathyroidism.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Severe hypercalcemia (Ca2+ > 2,65 mmol/L)
- •Severe hepatic dysfunction
- •Overdosage of digoxin
- •Hypersensitivity to vitamin D or overdosage of vitmain D
- •Parathyroidectomia in the past
- •< 18 years of age
- •Mentall illness
研究者
相似试验
招募中
4 期
The (cost)effectiveness of paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients.hyperparathyroidismincreased activity of the parathyroids1003394910029149NL-OMON31628Sint Lucas Andreas Ziekenhuis114
尚未招募
不适用
Research to (cost)effectiveness of paricalcitol in the treatment of secondary hyperparathyroidismNL-OMON24070Het Sint Lucas Andreas ziekenhuis114
尚未招募
不适用
Research to cost-effectiveness of paricalcitol of the treatment of secundary hyperparathyroidism at hemodialysis patientsNL-OMON24822Sint Lucas Andreas ziekenhuis114
进行中（未招募）
不适用
Efficacy and safety of paricalcitol in the reduction of secondary hyperparathyroidism after kidney transplantation.Secondary hyperparathyroidism after renal transplantationMedDRA version: 16.0Level: PTClassification code 10020708Term: Hyperparathyroidism secondarySystem Organ Class: 10014698 - Endocrine disordersEUCTR2013-001326-25-ESFundación SENEFRO
终止
4 期
Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis SubjectsSecondary HyperparathyroidismDialysisNCT00664430Abbott13